Skip to content

Search

Towards Improving Point-of-Care Diagnosis of Non-malaria Febrile Illness: A Metabolomics Approach

This study demonstrates the potential use of plasma metabolites to identify causality in children with severe febrile illness in malaria-endemic settings

Myositis complicating benzathine penicillin-G injection in a case of rheumatic heart disease

A 7-year old boy developed myositis secondary to intramuscular injection of benzathine penicillin-G in the context of secondary prophylaxis for RF

Acute rheumatic fever and rheumatic heart disease

Acute rheumatic fever (ARF) is the result of an autoimmune response to pharyngitis caused by infection with group A Streptococcus.

Missing voices: Profile and extent of acquired communication disorders in Aboriginal and non-Aboriginal adult stroke survivors in Western Australia

The needs of Aboriginal stroke patients with acquired communication disorder should inform appropriate service design for speech pathology and rehabilitation

Development of Group A streptococcal vaccines: an unmet global health need

This review provides an update on the current status of Group A Streptococcus vaccine development, & describes global efforts to accelerate the development...

Rheumatic heart disease in Indigenous children in northern Australia: Differences in prevalence and the challenges of screening

This study compared regional differences in the prevalence of rheumatic heart disease in Indigenous Australian children, and describes the logistical and...

Supply of benzathine penicillin G: the 20-year experience in Australia

Reliable supplies of BPG are essential for delivering the recommended schedule of secondary prophylaxis for people living with RHD.

Pharmacokinetics of intramuscular versus subcutaneous administration of Benzathine Penicillin G

Benzathine penicillin G (BPG) has been in use since the 1950s for treatment of skin infections, bacterial pharyngitis, syphilis and prevention of recurrent episodes of acute rheumatic fever (ARF)

Reach: to stop rheumatic heart disease

Reach works to promote the health of vulnerable populations by providing technical support to local, regional and global efforts to prevent and control rheumatic fever and rheumatic heart disease (RF/RHD).